

our main point

1. section 1: introduction begins here (suggestions: try writing your introductions last).
  - (a) what is my topic (question)?
  - (b) why is it important?
  - (c) how will I plan to proceed with my
2. previous comparative gene set enrichment analysis does not take....
3. we propose a method that allows DE within the test set as well as the background gene set.

# Competitive gene set enrichment analysis for correlated expression data

## Abstract

To be filled

## 1 Introduction

### What is enrichment analysis? Why would people care about that?

*Gene set test* is a method that studies the association between a list of genes that are significantly correlated with treatment or experimental design variables and a *prior* set of genes that are biologically related. A typical gene expression analysis involves the detection of a list of differentially expressed genes. Differential expression (DE) analysis focuses on individual genes, and therefore it fails to provide insight into the association of treatment variable with the gene set under study. Gene set test helps researchers better understand the underlying biological processes.

### What are the differences between self-contained and competitive test? And how does they work?

Depending on the definition of the null hypothesis, there are two types of gene set test: the *self-contained* and *competitive* test (Goeman and Bühlmann, 2007). A *self-contained* test evaluates a set of genes by a fixed standard without reference to other genes in the genome (Goeman et al., 2005; Wu et al., 2010). A *competitive* test examines genes in the test set to those not in the test set (Tian et al., 2005; Wu and Smyth, 2012; Yaari et al., 2013). Many methods, regardless of the type of test, perform a three-stage analysis (Khatri et al., 2012): on the first stage, a *gene-level statistic* that measures the association between the expression profiles and the experimental design variables is calculated for each gene; such gene-level statistics include, among others, signal-to-noise ration (Subramanian et al., 2005), moderated *t* statistics (Smyth, 2004) and *Z*-score (Efron, 2007). On the second stage, a *set-level statistic* is calculated by using gene-level statistics and prior information about the test set (i.e., whether the gene belongs to the set) as input. On the last stage, a *p*-value is assigned to the test set by comparing the set-level statistic to its reference distribution. The competitive gene set test is much more popular among genomic literatures (Goeman and Bühlmann, 2007; Gatti et al., 2010).

### Independent gene set test

Many competitive gene set tests rely on independence of gene regarding expression profiles (REF). Those tests are parametric or rank-based procedures that assume the gene-level statistics to be independent and identically distributed, or gene permutation procedures that generate the same approximate null (For what??). Examples include, among many others, *z*-test/*t*-test that compares the mean of the gene-level statistics in the test set to the mean of those not in the test (e.g., the PAGE procedure of Kim and Volsky, 2005), the  $2 \times 2$  contingency-table-based tests that examine the over-representation of DE genes in the test set (see Huang et al., 2009 for a review), and permutation-based tests that evaluate the set-level *p*-values by permuting gene labels (e.g., sigPathway of Tian et al., 2005, "gene-SetTest" in the limma package Smyth, 2004). However, tests assuming independence of genes may result in inflated false discovery rate (Efron and Tibshirani, 2007) as genes in a gene set are often correlated and function together (REF).

### Tests that account for between-gene correlations

A number of methods have been proposed to account for between-gene correlation in gene set tests. One attempt is to evaluate the set-level  $p$ -value by permuting the biological samples (see, for example, [Subramanian et al., 2005](#) and [Efron and Tibshirani, 2007](#)). Permuting the sample labels preserves, in contrast to permuting gene labels that ignores, the between-gene correlation structure and thus protects the test against such correlation. The very famous example of this kind is the *Gene Set Enrichment Analysis* (GSEA) proposed by [Subramanian et al. \(2005\)](#). However, this approach implicitly alters the null hypothesis being tested and therefore the null and the alternative hypotheses are difficult to characterize ([Khatri et al., 2012](#)). Another attempt is to conduct set-level test that works with the between-gene correlation structures. [Wu and Smyth \(2012\)](#) proposed Correlation Adjusted MEan RAnk (CAMERA) gene set test that estimates a variance inflation factor associated with correlations between gene expression profiles, and then incorporates it into the parametric or rank-based test. Estimating the variance inflation factor relies on the assumption that correlations between any two local statistics are almost the same as correlations between their corresponding expression profiles. However, as shown by (the paper to be finished), the correlations of local test statistics can be over-estimated by using sample correlations as approximation when a fraction of genes are DE. The CAMERA procedure thus may be too conservative for controlling type I error in the presence of DE genes, as we will demonstrate in our simulation study.

### What do we propose?

In this paper, we propose a new competitive gene set test procedure that takes into account the correlations among gene-level statistics in the set-level test. This procedure aims to correct for the discrepancy between correlations among expression profiles and those among gene-level statistics. Our strategy is to first model the covariance of gene-level statistics by two variance components, one attributable to the correlations among expression profiles and the other attributable to the DE effect caused by the treatment, and then incorporate the estimated covariance into the set-level statistics of our gene set test procedure. OurMethod works for a two group comparison experiment, and does not require any particular correlation structure.

### What is the plan of this paper?

## 2 Methods

**Overview of our method (denoted as OurMethod, will be easily replaced when we have a better new name)**

For a competitive gene set test, it is often unclear what the hypothesized null is, and thus what is being tested ([Barry et al. \(2008\)](#) [Wu and Smyth, 2012](#)).

### 2.1 The general assumptions for expression data

In a treatment-control gene expression experiment, we denote by  $Y_{ijk}$  a random variable for the expression level of gene  $i$  from observational unit  $j$  in treatment group  $k$ , with  $i$  taking the values  $1, \dots, m$  (the number of genes),  $j$  taking the values  $1, \dots, n_k$  (the total number of biological samples), and  $k$  being either 1 for control or 2 for treatment. Correspondingly,  $Y_{ijk}^*$  represents the standardized expression levels (described in REF???) for gene  $i$  of sample  $j$ , with  $Y_{ijk}^* \sim N(0, 1)$  (??? Normal assumption necessary here???) if sample  $j$  comes from the control group, and  $Y_{ijk}^* \sim N(\Delta_i, 1)$  if it comes from the treatment group. Here,  $\Delta_i$  is a *DE effect*: compared to the control group, gene  $i$  is not DE if  $\Delta_i = 0$ , up-regulated if  $\Delta_i > 0$  and down-regulated if  $\Delta_i < 0$ . In a gene expression experiment, the DE effect  $\Delta_i$  consists of two parts: 1) the treatment which determines whether a gene is DE or not; and 2) the DE effect size or strength when the gene is DE. For 1), we let  $\mathbf{Z} = (Z_1, \dots, Z_m)$  be a vector of DE indicators, where  $Z_i = 1$  if gene  $i$  is DE and  $Z_i = 0$  otherwise, and (DO WE NEED TO ASSUME  $Z_i$ s TO BE INDEPENDENT OF EACH OTHER?

$$Z_i \sim \text{Binom}(1, p_i) \tag{1}$$

For 2), we denote  $\delta_i$  as the *DE effect size* for gene  $i$  and  $\delta_i$  follows some distribution  $f_\delta$  with mean and variance

$$E(\delta_i) = \mu_\delta, \quad \text{Var}(\delta_i) = \sigma_\delta^2 \quad (2)$$

We further assume that the DE indicator  $Z_i$  is independent of the DE effect size  $\delta_i$  for gene  $i = 1, \dots, m$ . Therefore, the DE effect can be expressed as

$$\Delta_i = Z_i \delta_i, \quad (3)$$

It can be shown that (details in Appendix 7),

$$E(\Delta_i) = p_i \mu_\delta, \quad \text{Var}(\Delta_i) = p_i \sigma_\delta^2 + p_i(1 - p_i) \mu_\delta^2, \quad i = 1, \dots, m. \quad (4)$$

We assume that conditioning on the DE effects, expression levels for different samples are independent, but expression levels for different genes of the same sample may be correlated. Denote  $C_{m \times m}$  as the gene correlation matrix, with entry  $\rho_{i_1, i_2}$  being the correlation between genes  $i_1$  and  $i_2$ . Note that the between-gene correlation  $\rho_{i_1, i_2}$  is a constant, regardless of whether the sample is from the treatment or from the control group.

## 2.2 Gene set test allowing for between-gene correlation

We denote by  $I_t$  and  $I_b$  the gene set being tested and background set (i.e., the genes not in the test set). Let  $\mathbf{x} = (x_1, \dots, x_m)$  be a indicator vector of whether or not gene  $i$  belongs to the test set and thus  $I_t = \{i : x_i = 1\}$  and  $I_b = \{i : x_i = 0\}$ . We assume that the DE probability is  $p_t$  for genes in the test set and  $p_b$  for genes in the background set. For gene  $i$ , denote  $U_i = \bar{Y}_{i,2} - \bar{Y}_{i,1}$  as the difference in mean expression levels between the treatment and the control group, where  $\bar{Y}_{i,k} = \sum_{j=1}^{n_k} Y_{ijk} / n_k$ . It follows from equation (4) that  $\mathbf{U} = (U_1, \dots, U_m)$  has mean

$$E(U_i) = \begin{cases} p_t \mu_\delta, & \text{if } i \in I_t \\ p_b \mu_\delta, & \text{if } i \in I_b \end{cases} \quad (5)$$

and covariance (see Appendix 7 for detail)

$$\text{Var}(\mathbf{U}) = \mathbf{D} + \sigma_2^2 \mathbf{C} \quad (6)$$

where  $\mathbf{D} = \text{diag}(d_1, \dots, d_m)$  with  $d_i = p_t \sigma_\delta^2 + p_t(1 - p_t) \mu_\delta^2$  if  $i \in I_t$  and  $d_i = p_b \sigma_\delta^2 + p_b(1 - p_b) \mu_\delta^2$  if  $i \in I_b$ ,  $\sigma_2^2 = \frac{1}{n_1} + \frac{1}{n_2}$  and  $\mathbf{C}$  is the between-gene correlation matrix.

**(The test)** The DE probability affects both the mean vector in equation (5) and the covariance in equation (6). Under this framework, the test set is not enriched only if the probability of DE in the test set is the same as that in the background set. Therefore, the hypothesis for enrichment testing can be statistically formulated as

$$H_0: p_t = p_b \stackrel{\text{def}}{=} p_0 \text{ Versus } H_1: p_t \neq p_b \quad (7)$$

We can combine equations (5) and (6) into the following linear model

$$\mathbf{U} = \beta_0 \mathbf{1}_m + \beta_1 \mathbf{x} + \boldsymbol{\epsilon}, \quad \text{Cov}(\boldsymbol{\epsilon}) = \mathbf{D} + \sigma_2^2 \mathbf{C} \quad (8)$$

with  $\beta_0 = p_b \mu_\delta$ ,  $\beta_1 = (p_t - p_b) \mu_\delta$  and  $\mathbf{1}_m$  being a vector of ones. Now the hypothesis testing problem in (7) becomes

$$H_0: \beta_1 = 0 \text{ Versus } H_1: \beta_1 \neq 0. \quad (9)$$

Under the null of (9), we have  $E(\mathbf{U}) = \beta_0 \mathbf{1}_m$  and  $\text{Var}(\mathbf{U}) = \sigma_1^2 \mathbf{I}_m + \sigma_2^2 \mathbf{C}$  where  $\mathbf{I}_m$  is an identity matrix and  $\sigma_1^2 = p_0 \sigma_\delta^2 + p_0(1 - p_0) \mu_\delta^2$ .

**(Estimating the parameters)** In practice, we need to estimate  $\beta_0$ ,  $\sigma_1^2$  and  $\mathbf{C}$  in model 8 for enrichment test. Our strategy is to use *quasi-likelihood*, which requires only the mean and the variance of  $\mathbf{U}$ . The between-gene correlation matrix  $\mathbf{C}$  is estimated by the residual sample correlations after

the treatment differences have been nullified (the same as is done by Efron (2007) or Wu and Smyth (2012)), and is treated as known in estimating  $\beta_0$  and  $\sigma_1^2$ . Denoting  $\hat{\mathbf{C}}$  as the estimate of  $\mathbf{C}$  and,

$$\mathbf{\Sigma} = \sigma_1^2 \mathbf{I}_m + \sigma_2^2 \hat{\mathbf{C}} \quad (10)$$

The score equations for  $\beta_0$  and  $\sigma_1^2$  are

$$\begin{aligned} (\mathbf{U} - \beta_0 \mathbf{1}_m)^T \mathbf{\Sigma}^{-1} \mathbf{1}_m &= 0 \\ (\mathbf{U} - \beta_0 \mathbf{1}_m)^T \mathbf{\Sigma}^{-1} \hat{\mathbf{C}} (\mathbf{U} - \beta_0 \mathbf{1}_m) &= \text{trace}(\mathbf{\Sigma}^{-1} \hat{\mathbf{C}}) \end{aligned} \quad (11)$$

.... something to catch up.....

The enrichment test statistic for the test set is

$$T = \frac{\left[ \mathbf{x}^T (\mathbf{U} - \hat{\beta}_0 \mathbf{1}_m) \right]^2}{\left[ \mathbf{x}^T (\mathbf{I} - \mathbf{H}) \right] \mathbf{\Sigma} \left[ \mathbf{x}^T (\mathbf{I} - \mathbf{H}) \right]^T} \quad (12)$$

Under the null,  $T \sim \chi^2(1)$ .

### 2.3 Other competitive gene set tests

We will compare OurMethod to three existing gene set tests: GSEA (Subramanian et al., 2005) modified from the original R-GSEA script (<http://software.broadinstitute.org/gsea/index.jsp>) to accommodate single gene set test, two versions of the CAMERA procedure (Wu and Smyth, 2012), and two versions of the geneSetTest procedure in the limma package (Smyth, 2005). By "two versions" we mean, respectively, parametric and rank based. We will denote the two versions by geneSetTest-modt and geneSetTest-rank for geneSetTest, and by CAMERA-modt and CAMERA-rank for CAMERA. Because GSEA and OurMethod do not support linear models, the implementations are restricted to two-group comparisons.

All of the three tests use local genewise statistics as observations to conduct set-level tests comparing genes in the test set to those in the background set. They may differ, however, either in terms of the gene-level statistics used to compare factors of interest (e.g. treatment vs. control) at the gene level, or in terms of the set-level statistics used to summarize the significance of the test set compared to the background set. For GSEA, the gene-level statistics are the rankings of genes according to a ranking metric (e.g. signal-to-noise ratio,  $t$ -statistic), then based on the rankings an enrichment score for the test set is calculated, and the significance of the enrichment score is determined by randomly permuting the sample labels. For the parametric version, both CAMERA-modt and geneSetTest-modt use certain type of gene-level statistics (e.g., the moderated  $t$ -statistics Smyth (2004)), and determine whether the means of the gene-level statistics are significantly different for genes in the test set versus genes in the background set. The difference is how they evaluate the set-level statistics: CAMERA-modt uses a  $t$ -statistic that allows the gene-level statistics in the test set to be correlated by first estimating a variance inflation factor, and then incorporating it into the  $t$ -statistic to adjust for between-gene correlation (see materials and methods section of Wu and Smyth (2012)); geneSetTest-modt evaluates  $p$ -values by comparing the observed mean of the gene-level statistics in the test set, to those (??? is it clear?) obtained by randomly permuting the gene labels. For the rank-based test, CAMERA-rank and geneSetTest-rank conduct a Wilcoxon-Mann-Whitney rank sum test, and they amount to, respectively, CAMERA-modt and geneSetTest-modt in that they compare the rankings instead of the gene-level statistics themselves for genes in the test set to those for genes in the background set.

## 3 Examples and Numerical Results

### 3.1 Simulations

In this section, we present results from type I error and power simulations under a range of between-gene correlation structures.

The simulations run as follows: first, we simulate an entire gene set containing  $m = 500$  genes, from which we sample  $m_1 = 100$  genes to represent those in the test set, and the remaining  $m_2 = 400$  genes those in the background set; second, for gene  $i = 1, \dots, m$ , we simulate the DE effect  $\Delta_i$  by first generating the DE size  $\delta_i$  from  $N(0.5, 1)$  and the DE indicator  $Z_i$  from  $\text{Binom}(1, p_i)$ , where  $p_i = p_t$  if gene  $i$  belongs to the test set and  $p_i = p_b$  otherwise, and then setting  $\Delta_i$  to be the product of  $Z_i$  and  $\delta_i$ ; third, we set the "true" mean expression values  $\mu_1 = \mathbf{0}_m$  and  $\mu_2 = \Delta$ , respectively, for the control and treatment groups; fourth, we simulate  $n_1$  samples from  $\text{MVN}(\mu_1, \Sigma)$  for the control group and  $n_2$  samples from  $\text{MVN}(\mu_2, \Sigma)$ , where the covariance  $\Sigma = (\sigma_{i_1, i_2})_{m \times m}$  may take one of the following forms:

- (a0): the genes are independent of each other (i.e.,  $\Sigma = \mathbf{I}_m$ ).
- (a): only the genes in the test set are correlated, with exchangeable correlation structure, that is,  $\text{Cor}(Y_{i_1}, Y_{i_2}) = \sigma_{i_1, i_2} = \rho$  for  $\forall i_1, i_2 \in I_t$  and  $\text{Cor}(Y_{i_3}, Y_{i_4}) = \sigma_{i_3, i_4} = 0$  if at least one of  $i_3, i_4$  does not belong to  $I_t$ .
- (c): all genes are correlated, with exchangeable correlation structure, that is,  $\text{Cor}(Y_{i_1}, Y_{i_2}) = \sigma_{i_1, i_2} = \rho$  for  $\forall i_1, i_2 \in I$ .
- (e): genes are correlated within the test set and within the background set; but any two genes, one from the test set and the other from the background set, are independent. That is, the correlation structure is block diagonal, with  $\text{Cor}(Y_{i_1}, Y_{i_2}) = \sigma_{i_1, i_2} = \rho_1$  for  $i_1, i_2 \in I_t$ ,  $\text{Cor}(Y_{i_3}, Y_{i_4}) = \sigma_{i_3, i_4} = \rho_2$  for  $i_3, i_4 \in I_b$ , and  $\text{Cor}(Y_{i_5}, Y_{i_6}) = \sigma_{i_5, i_6} = 0$  for  $\forall i_5 \in I_t, \forall i_6 \in I_b$ .
- (f): all genes are correlated, but the correlation between two genes depend on whether they belong to the test set or not. Specifically,  $\text{Cor}(Y_{i_1}, Y_{i_2}) = \sigma_{i_1, i_2} = \rho_1$  for  $i_1, i_2 \in I_t$ ,  $\text{Cor}(Y_{i_3}, Y_{i_4}) = \sigma_{i_3, i_4} = \rho_2$ , for  $i_3, i_4 \in I_b$ , and  $\text{Cor}(Y_{i_5}, Y_{i_6}) = \sigma_{i_5, i_6} = \rho_3$  for  $\forall i_5 \in I_t, \forall i_6 \in I_b$ .
- (g): genes are correlated in the same way as those from a real data.

### 3.1.1 Type I error simulations

In the above simulation setup, the test set is not enriched if DE probabilities are the same for the genes in the test set and for those in the background set (i.e.,  $p_t = p_b = p_0$ ). However, it is shown in (the paper to be finished) that the test statistics correlation between two genes is not equal to their sample correlation when at least one gene is truly DE (under two sample  $t$ -test??). Therefore, if there are true DE genes in the entire gene set, approaches assuming the same correlation between gene-level statistics and between expression values may not perform well. To illustrate this point, we performed two groups of simulations for each of the correlation structures above: in group  $A_1$ , we simulated expression data with no DE genes (i.e.,  $p_t = p_b = 0$ ); and in group  $A_2$ , we simulated data sets with the same DE probabilities for all genes (i.e., DE probabilities are the same for genes in the test set and for those in the background set with  $p_t = p_b = 0.2$ ).

For group  $A_1$ , Figure 1 shows the histograms of type I error rates for the six approaches (OurMethod, geneSetTest-modt, geneSetTest-rank, CAMERA-modt, CAMERA-rank and GSEA) under the six correlation structures. OurMethod and GSEA hold the size of type I error rates correctly for all 6 correlation structures, with simulated  $p$ -values uniformly distributed on  $[0, 1]$ . The two version of CAMERA control type I errors correctly for correlation structures (a0) and (a). However, both are too conservative for the case of (c) and (g), and anti-conservative for correlation structures (e) and (f). geneSetTest procedures may be too liberal depending on the underlying correlation structures.

For the group  $A_2$  simulation where DE probabilities are 0.2 across all genes, we summarize the results of the type I error rate simulation in Table 1. OurMethod continues to hold the size of type I error rates under all six correlation structures. However, GSEA is highly skewed towards small  $p$ -values and the two versions of CAMERA procedures are too conservative under all correlation structures, and the only exception is that CAMERA controls type I error rates correctly for (a0) where genes are simulated to be independent. The two versions of geneSetTest performs reasonably well.

### Explain why this happens

Consistent accuracy is shown for OurMethod across all simulations, but the accuracy of the other three methods may be affected by two factors: the between-gene correlation structures, and DE probability of each gene. OurMethod controls the size of type I error rates well because it takes into account the between-gene correlation and works directly with the sample correlation between genes, and therefore is robust against the two factors. (rewrite from here, because this is only my understanding.) The GSEA evaluates the enrichment score of a test set by generating its null distribution from sample permutation, and therefore the between-gene correlation is preserved when there are no DE genes, but [explain when DE exists]... For CAMERA, the set-level statistics take into account only the between-gene correlation in the test set, and therefore does not work for cases where genes in the background set are also correlated in group  $A_1$  simulations. More importantly, according to (the paper to be finished), the variance inflation factor of the gene-level statistics (moderated  $t$ -test in [Wu and Smyth \(2012\)](#)) may be over-estimated when a fraction of genes are DE, and therefore the set-level test statistic is under-estimated, resulting in conservative  $p$ -values in group  $A_2$  simulations. geneSetTest permutes the gene labels to examine the significance of the test set, and therefore it relies on independence between genes. The performances of both versions of geneSetTest are thus unpredictable in group  $A_1$ . In group  $A_2$  where there are DE genes both in the test set and in the background set, the correlation between the gene-level statistics are smaller (in absolute value) than the correlation between the genes. Since the genes are simulated to be slightly correlated ( $\rho_1 = 0.1, \rho_2 = 0.05, \rho_3 = -0.05$ ), the correlation between the gene-level statistics are almost negligible for geneSetTest procedure.

Table 1: Type I error rate of gene set tests for correlated expression values

Method	Norminal $p$ -values				Norminal $p$ -values			
	0.01	0.05	0.1	0.2	0.01	0.05	0.1	0.2
	(a0)				(a)			
OurTest	0.012	0.066	0.124	0.241	0.011	0.049	0.097	0.198
geneSetTest-modt	0.012	0.058	0.109	0.215	0.006	0.052	0.099	0.219
geneSetTest-rank	0.012	0.055	0.110	0.214	0.018	0.060	0.116	0.202
CAMERA	0.006	0.059	0.135	0.217	0.000	0.000	0.000	0.006
CAMERA-Rank	0.003	0.054	0.112	0.229	0.001	0.009	0.023	0.079
GSEA	0.989	0.995	0.997	0.997	0.228	0.608	0.794	0.927
	(c)				(e)			
OurTest	0.007	0.052	0.103	0.202	0.008	0.056	0.093	0.207
geneSetTest-modt	0.007	0.051	0.098	0.187	0.015	0.058	0.106	0.217
geneSetTest-rank	0.006	0.050	0.106	0.190	0.024	0.082	0.138	0.225
CAMERA	0.000	0.000	0.000	0.000	0.000	0.000	0.001	0.009
CAMERA-Rank	0.000	0.000	0.000	0.000	0.000	0.020	0.054	0.127
GSEA	0.942	0.984	0.992	0.995	0.108	0.469	0.731	0.899
	(f)				(g)			
OurTest	0.012	0.050	0.098	0.226	0.007	0.059	0.116	0.211
geneSetTest-modt	0.010	0.071	0.115	0.213	0.010	0.061	0.104	0.218
geneSetTest-rank	0.007	0.061	0.112	0.221	0.014	0.072	0.142	0.247
CAMERA	0.000	0.000	0.004	0.019	0.000	0.000	0.001	0.006
CAMERA-Rank	0.006	0.041	0.096	0.210	0.000	0.000	0.002	0.009
GSEA	0.015	0.188	0.434	0.770	0.943	0.975	0.983	0.992

### 3.1.2 Power simulation

WHAT TO PRESENT

Figure 1: Type I error rates for gene set tests,  $p$ -value distribution for case (a0) - (g) from left to right, from top to bottom, NO gene is DE







Figure 2: Type I error rates for gene set tests,  $p$ -value distribution for case (a0) - (g) from left to right, from top to bottom, DE = 20%



### 3.2 Maybe real data analysis???

## 4 Discussion

There are many methods developed for gene set tests (see reviews by [Huang et al. \(2009\)](#); [Khatri et al. \(2012\)](#); [Tarca et al. \(2013\)](#)). Using the terminology of [Khatri et al. \(2012\)](#), these methods generally fall into three categories: *over-representation analysis*, *functional class scoring* and *pathway topology*. The over-representation analysis evaluates a fraction of genes among a set of pre-selected interesting genes (e.g., differentially expressed genes between treatment versus control samples). The test is usually conducted in the form of  $2 \times 2$  table, for example, GStat of [Klebanov et al. \(2007\)](#) and GO:TermFinder of [Tian et al. \(2005\)](#). However, the over-representation analysis methods have inherent limitations such as information loss by choosing arbitrary threshold (e.g.,  $p$ -value  $< 0.05$ ), or problematic assumption of independence of genes ([Goeman and Bühlmann \(2007\)](#); [Wu and Smyth \(2012\)](#)). The functional class scoring performs three-stage analysis ([Khatri et al., 2012](#)): on the first stage, a *gene-level statistic* that measures the association between the expression profiles and the experimental design variables is calculated for each gene; such gene-level statistics include, among others, signal-to-noise ration ([Subramanian et al., 2005](#)), moderated  $t$  statistics ([Smyth, 2004](#)) and  $Z$ -score ([Efron, 2007](#)). On the second stage, a *set-level statistic* is calculated by using gene-level statistics and prior information about the test set (i.e., whether the gene belongs to the set) as input. On the last stage, a  $p$ -value is assigned to the test set by comparing the set-level statistic to its reference distribution. (Rewrite this part)

The pathway topology will not be discussed in this paper ([Khatri et al. \(2012\)](#); [Tarca et al. \(2013\)](#))

## 5 Conclusion

## 6 Acknowledgements

## 7 Appendix

First  $E(\Delta_i) = E(Z_i\delta_i) = E(Z_i)E(\delta_i) = p_i\mu_\delta$ . Next note that

$$\text{Var}(\Delta_i) = E[(Z_i\delta_i)^2] - [E(Z_i\delta_i)]^2 = \text{Var}(Z_i)[E(\delta_i)]^2 + [(EZ_i)^2 + \text{Var}(Z_i)] \text{Var}(\delta_i) = p_i\sigma_\delta^2 + p_i(1-p_i)\mu_\delta^2$$

Let  $T_i = \bar{Y}_{i,2} - \bar{Y}_{i,1}$  be the difference in mean expression levels between the treatment group and the control group. We have

$$E(T_i) = E(\bar{Y}_{i,2}) - E(\bar{Y}_{i,1}) = E(\Delta_i) = E(Z_i\delta_i) = p_i\mu_\delta$$

The covariance between two genes  $i_1$  and  $i_2$  is given by (I HAVE CONCERNS HERE, IS IT VALID TO ASSUME THAT DE EFFECTS ARE INDEPENDENT BETWEEN GENES? WE SEE CO-EXPRESSION!! OR WE'VE ALREADY TAKEN THAT INTO ACCOUNT BY "CORRELATION BETWEEN GENES"),

$$\begin{aligned} \text{Cov}(T_{i_1}, T_{i_2}) &= E[\text{Cov}(T_{i_1}, T_{i_2} | \Delta_{i_1}, \Delta_{i_2})] + \text{Cov}[E(T_{i_1} | \Delta_{i_1}), E(T_{i_2} | \Delta_{i_2})] \\ &= E\left(\frac{1}{n_1}\rho_{i_1, i_2} + \frac{1}{n_2}\rho_{i_1, i_2}\right) + \text{Cov}(\Delta_{i_1}, \Delta_{i_2}) \\ &= \left(\frac{1}{n_1} + \frac{1}{n_2}\right)\rho_{i_1, i_2} \end{aligned} \tag{13}$$

For gene  $i$ , the variance  $\text{Var}(T_i) = \text{Var}(\bar{Y}_{i,1}) + \text{Var}(\bar{Y}_{i,2})$ , with

$$\text{Var}(\bar{Y}_{i,1}) = \frac{1}{n_1}$$

$$\begin{aligned}
\text{Var}(\bar{Y}_{i,2}) &= \frac{1}{n_2^2} \left[ \sum_{j=1}^{n_2} \text{Var}(Y_{ij2}) + 2 \sum_{1 \leq j_1 < j_2 \leq n_2} \text{Cov}(Y_{ij_1 2}, Y_{ij_2 2}) \right] \\
&= \frac{1}{n_2} \text{Var}(Y_{ij2}) + \frac{n_2 - 1}{n_2} \text{Cov}(Y_{ij_1 2}, Y_{ij_2 2}) \\
&= \frac{1}{n_2} [E(\text{Var}(Y_{ij2}|\Delta_i)) + \text{Var}(E(Y_{ij2}|\Delta_i))] \\
&\quad + \frac{n_2 - 1}{n_2} [E(\text{Cov}(Y_{ij_1 2}, Y_{ij_2 2}|\Delta_i)) + \text{Cov}(E(Y_{ij_1 2}|\Delta_i), E(Y_{ij_2 2}|\Delta_i))] \\
&= \frac{1}{n_2} + \text{Var}(\Delta_i)
\end{aligned} \tag{14}$$

Therefore  $\text{Var}(T_i) = \frac{1}{n_1} + \frac{1}{n_2} + \text{Var}(\Delta_i)$ , and it follows that

$$\text{Cov}(\mathbf{T}) = \mathbf{D} + \sigma_2^2 \mathbf{C} \tag{15}$$

where  $\mathbf{D}$  is a diagonal matrix with  $\text{Var}(\Delta_i) = p_i \sigma_\delta^2 + p_i(1 - p_i) \mu_\delta^2$  as its  $i$ th diagonal element, and  $\sigma_2^2 = \left( \frac{1}{n_1} + \frac{1}{n_2} \right)$ .

## References

- Barry, W. T., Nobel, A. B., and Wright, F. A. (2008). A statistical framework for testing functional categories in microarray data. *The Annals of Applied Statistics*, pages 286–315.
- Efron, B. (2007). Correlation and large-scale simultaneous significance testing. *Journal of the American Statistical Association*, 102(477).
- Efron, B. and Tibshirani, R. (2007). On testing the significance of sets of genes. *The annals of applied statistics*, pages 107–129.
- Gatti, D. M., Barry, W. T., Nobel, A. B., Rusyn, I., and Wright, F. A. (2010). Heading down the wrong pathway: on the influence of correlation within gene sets. *BMC genomics*, 11(1):574.
- Goeman, J. J. and Bühlmann, P. (2007). Analyzing gene expression data in terms of gene sets: methodological issues. *Bioinformatics*, 23(8):980–987.
- Goeman, J. J., Oosting, J., Cleton-Jansen, A.-M., Anninga, J. K., and Van Houwelingen, H. C. (2005). Testing association of a pathway with survival using gene expression data. *Bioinformatics*, 21(9):1950–1957.
- Huang, D. W., Sherman, B. T., and Lempicki, R. A. (2009). Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic acids research*, 37(1):1–13.
- Khatri, P., Sirota, M., and Butte, A. J. (2012). Ten years of pathway analysis: current approaches and outstanding challenges. *PLoS Comput Biol*, 8(2):e1002375.
- Kim, S.-Y. and Volsky, D. J. (2005). Page: parametric analysis of gene set enrichment. *BMC bioinformatics*, 6(1):144.
- Klebanov, L., Glazko, G., Salzman, P., Yakovlev, A., and Xiao, Y. (2007). A multivariate extension of the gene set enrichment analysis. *Journal of bioinformatics and computational biology*, 5(05):1139–1153.
- Smyth, G. K. (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat. Appl. Genet. Mol. Biol.*, 3, Article3.
- Smyth, G. K. (2005). Limma: linear models for microarray data. In *Bioinformatics and computational biology solutions using R and Bioconductor*, pages 397–420. Springer.
- Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proceedings of the National Academy of Sciences of the United States of America*, 102(43):15545–15550.
- Tarca, A. L., Bhatti, G., and Romero, R. (2013). A comparison of gene set analysis methods in terms of sensitivity, prioritization and specificity.
- Tian, L., Greenberg, S. A., Kong, S. W., Altschuler, J., Kohane, I. S., and Park, P. J. (2005). Discovering statistically significant pathways in expression profiling studies. *Proceedings of the National Academy of Sciences of the United States of America*, 102(38):13544–13549.
- Wu, D., Lim, E., Vaillant, F., Asselin-Labat, M.-L., Visvader, J. E., and Smyth, G. K. (2010). Roast: rotation gene set tests for complex microarray experiments. *Bioinformatics*, 26(17):2176–2182.
- Wu, D. and Smyth, G. K. (2012). Camera: a competitive gene set test accounting for inter-gene correlation. *Nucleic acids research*, 40(17):e133–e133.
- Yaari, G., Bolen, C. R., Thakar, J., and Kleinstein, S. H. (2013). Quantitative set analysis for gene expression: a method to quantify gene set differential expression including gene-gene correlations. *Nucleic acids research*, page gkt660.